A rally for US stocks came closer to fading out on Wednesday, with indexes stalling near their record levels.
Three new stocks make our Safest Dividend Yield Model Portfolio this month. Get a free look at one of the stocks in this month’s portfolio.
This article will look at companies reviewed by ModernGraham which have grown their dividends annually for at least the last 20 years.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
In its core uniform and facility services unit (80% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (6% of sales), and a uniform direct sales business (3% of sales).
| Website: | www.cintas.com |
| Main Phone: | +1 513 459-1200 |
| Address: | 6800 Cintas Boulevard |
| Address 2: | P.O. Box 625737 |
| State: | OH |
| City / Town: | Cincinnati |
| Country: | US |
| Postal Code: | 45262-5737 |
| Exchange: | NGS |
| CEO: | Scott D. Farmer |
| Employees: | 40000 |
| NAICS: | All Other Business Support Services(561499) |
A rally for US stocks came closer to fading out on Wednesday, with indexes stalling near their record levels.
Three new stocks make our Safest Dividend Yield Model Portfolio this month. Get a free look at one of the stocks in this month’s portfolio.
This article will look at companies reviewed by ModernGraham which have grown their dividends annually for at least the last 20 years.
The last few years have been the spring of hope for NPK’s thriving Defense segment, but they’ve been the winter of despair for its Housewares/Small Appliances business.
BRAFTOVI + MEKTOVI combination approved for advanced BRAF-mutant melanoma.
Singapore-based oncology-focused company targeting diseases that are both highly prevalent in Asia and that have orphan indications in the US and Europe.
To develop and commercialize a multi-gene panel for broad tumor profiling, leading to a next generation sequencing based companion diagnostic.
Median progression-free survival of 14.9 months using encorafenib and binimetinib together.
At Equities.com we’re interested in the disparity between performance and analyst proselytizing, which inspired us back in June to look at six specific biotech plays that had lost value on
With only three days left in the 2013 baseball season, most of the playoff teams have been set and we can look back on a wild ride. Miguel Cabrera flirted with his second straight triple crown,
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
